Glucagon-like peptide 1 (GLP-1) receptor agonists. GLP-1 receptor agonists are primarily indicated for the treatment of type 2 diabetes to improve glycemic control by stimulating insulin secretion and inhibiting glucagon release. This evidence concerns the gene GCG and type 2 diabetes mellitus.